Recommendations for pediatric tuberculosis vaccination in Italy

Carlotta Montagnani, Susanna Esposito, Luisa Galli, Elena Chiappini, Nicola Principi, M. de Martino, Samantha Bosis, Samantha Bosis, Claudia Tagliabue, B. Ascolese, Alberto Villani, Alberto Villani, Laura Lancella, Annalisa Grandin, C. Marabotto, Luisa Galli, Elena Chiappini, D. Ciofi, Filippo Festini, Martina AnziatiSabrina Becciani, Giulia Remaschi, Sara Sollai, Chiara Tersigni, Elisabetta Venturini, A. Guarino, A. L O Vecchio, Ricardo Scotto, Clara Gabiano, Silvia Garazzino, Daniele Le Serre, Irene Raffaldi, F. Bernardi, Elisa Bertazzoni, Francesco Blasi, Francesco Blasi, L. R. Assante, Elio Castagnola, Elio Castagnola, Giuseppe Losurdo, Giuseppe Di Mauro, Marino Faccini, Gianluigi Marseglia, Gianluigi Marseglia, Amelia Di Comite, Amelia Di Comite, Mauro Stronati, Giovanni Battista Migliori, Giovanni Battista Migliori, Rosella Centis, Rosella Centis, Daniela Cirillo, Daniela Maria Cirillo, Enrico Tortoli, Cristina Russo, Elisabetta Scala, Paolo Tomà, Gianluigi Marseglia

Research output: Contribution to journalReview articlepeer-review

Abstract

Bacillus Calmette-Guérin (BCG) vaccine is still the only vaccine approved for the prevention of tuberculosis (TB), and is widely used in highly endemic countries, where all newborns receive a single intradermal dose immediately after birth; however, the recommendations concerning its use in Europe vary widely from country to country. This document describes the recommendations of a group of Italian scientific societies concerning its pediatric use in Italy, the persistence of the protection it provides, its safety, its interference with tuberculin skin test (TST) responses, and the children who should be vaccinated. The experts conclude that BCG vaccination provides a good level of protection against tuberculous meningitis and disseminated forms, and a fair level of protection against pulmonary disease; the protective effective lasts at least 10 years, and revaccination offers no advantages over a single administration. The vaccine is safe in immunocompetent subjects, and affects the response to a TST for at least 6 y On the basis of these observations, we recommend its use in Italy in all TST-negative immunocompetent newborns and breastfeeding infants aged <6 months, and all TST-negative children aged between 6 months and 5 y who come from highly epidemic areas, or whose parents come from highly endemic areas, or who have been in contact with a family member with active TB without contracting the disease themselves.

Original languageEnglish
Pages (from-to)644-650
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume12
Issue number3
DOIs
Publication statusPublished - Mar 3 2016

Keywords

  • BCG
  • children
  • prevention
  • tuberculosis
  • vaccination
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Recommendations for pediatric tuberculosis vaccination in Italy'. Together they form a unique fingerprint.

Cite this